Purdue offers grant to fund Fla. Rx monitoring program
STAMFORD, Conn. — Drug maker Purdue Pharma is giving a $1 million grant to the state of Florida to help fund the state’s prescription drug monitoring program, the company said Wednesday.
Purdue said the program was designed to combat illegal diversion and abuse of prescription drugs. Purdue is the maker of OxyContin (oxycodone), an extended-release opioid painkiller that often is a target of abuse.
The company also is giving a $1 million grant to the National Association of Boards of Pharmacy to support the group’s program to help state prescription drug monitoring programs detect “doctor shopping” across state lines.
Tris seeks FDA OK for allergy treatment for kids
MONMOUTH JUNCTION, N.J. — The Food and Drug Administration has accepted a regulatory approval application from Tris Pharma for a drug to treat allergies in children ages 2 years and older, Tris said Wednesday.
Tris said that if approved, its carbinoxamine extended-release oral suspension would provide an alternative to currently available immediate-release formulations.
Carbinoxamine is a mildly sedating antihistamine. Before 2006, it was widely used, with more than 100 products containing the drug, but nearly all were older drugs that hadn’t undergone the FDA’s approval process. The agency removed all of them except two immediate-release formulations.
DiabetesMine launches 2011 design challenge
SAN FRANCISCO — An informational and community website for people with diabetes has kicked off its fourth annual design challenge, a Web-based competition that calls for fresh ideas for new devices, Web applications or other instruments designed to help people live better with the disease.
DiabetesMine, which is part of the Alliance Health Networks family of sites, said the 2011 design challenge fosters innovation. For the second year in a row, open community voting on the website will determine the top 10 finalists for this competition. Final winner selections will be made by a group of expert judges with expertise in diabetes care, medical technologies, design and venture capital funding. Three winners will be announced this year, with the grand prize winner awarded a cash prize and the opportunity to attend an industry event, as well as meet with experts.
"We’re very excited to expand the reach of the contest this year," said Amy Tenderich, DiabetesMine founder and Type 1 diabetic. "Not only do we look forward to another bounty of creative submissions, but we’re also planning a Diabetes Innovation Summit event that will bring together patient advocates, medical device designers, investors and other experts. It’s all about making ‘patient-centered care’ a truly meaningful term."
For DiabetesMine 2011 design challenge information, visit DiabetesMine.com.